替瑞利尤单抗联合阿替利珠单抗对比安慰剂联合阿替利珠单抗一线治疗PD-L1选择性非小细胞肺癌(CITYSCAPE):随机双盲2期研究的主要与随访分析
CITYSCAPE是一项2期随机双盲安慰剂对照试验,纳入化疗初治、PD-L1阳性(TPS≥1%)、无EGFR或ALK变异的复发或转移性非小细胞肺癌患者,按1:1随机接受替瑞利尤单抗(600 mg)联合阿替利珠单抗(1200 mg)或安慰剂联合阿替利珠单抗静脉给药每3周一次。主要分析时中位随访5.9个月,联合组客观缓解率31.3% vs 安慰剂组16.2%(p=0.031),中位无进展生存期5.4个月 vs 3.6个月(分层HR 0.57,95%CI 0.37-0.90,p=0.015)。
要点
- 替瑞利尤单抗联合阿替利珠单抗较安慰剂联合阿替利珠单抗改善客观缓解率(31.3% vs 16.2%,p=0.031)。
- 联合组中位无进展生存期5.4个月 vs 安慰剂组3.6个月,分层HR 0.57(95%CI 0.37-0.90,p=0.015)。
- 联合组治疗相关严重不良事件14例(21%) vs 安慰剂组12例(18%),联合组发生2例治疗相关死亡。
核心结论
- 在化疗初治、PD-L1阳性、复发或转移性非小细胞肺癌患者中,替瑞利尤单抗联合阿替利珠单抗较安慰剂联合阿替利珠单抗在客观缓解率和无进展生存期上显示出有临床意义的改善。
- 替瑞利尤单抗联合阿替利珠单抗耐受性良好,安全性特征与阿替利珠单抗单药总体相似。
- 这些发现表明替瑞利尤单抗联合阿替利珠单抗是治疗既往未治疗、局部晚期不可切除或转移性非小细胞肺癌的一种有前景的免疫联合方案。
研究设计与样本
- CITYSCAPE为2期随机双盲安慰剂对照试验,自欧洲、亚洲和美国的41家诊所入组患者。
- 入组条件为化疗初治、PD-L1阳性(22C3免疫组化pharmDx检测肿瘤比例评分≥1%)、复发或转移性非小细胞肺癌、有可测量病灶、ECOG体能状态0或1、无EGFR或ALK变异。
- 患者按1:1通过交互式语音或网络应答系统随机接受替瑞利尤单抗(600 mg)联合阿替利珠单抗(1200 mg)或安慰剂联合阿替利珠单抗静脉给药每3周一次。
- 共同主要终点为意向治疗人群中研究者按RECIST 1.1评估的客观缓解率和无进展生存期,在主要人群观察到约80例无进展生存事件后分析。
- 安全性在所有至少接受一剂研究药物的患者中评估;患者于2018年8月10日至2019年3月20日入组,主要分析数据截止日期为2019年6月30日。
主要发现
- 主要分析时275例患者接受资格评估,135例被随机分配至替瑞利尤单抗联合阿替利珠单抗组(67例[50%])或安慰剂联合阿替利珠单抗组(68例[50%])。
- 中位随访5.9个月(4.6-7.6,意向治疗人群)时,替瑞利尤单抗联合阿替利珠单抗组21例(31.3%[95%CI 19.5-43.2]) vs 安慰剂联合阿替利珠单抗组11例(16.2%[6.7-25.7])达到客观缓解(p=0.031)。
- 替瑞利尤单抗联合阿替利珠单抗组中位无进展生存期5.4个月(95%CI 4.2-不可估计) vs 安慰剂联合阿替利珠单抗组3.6个月(2.7-4.4),分层风险比0.57(95%CI 0.37-0.90),p=0.015。
- 替瑞利尤单抗联合阿替利珠单抗组14例(21%) vs 安慰剂联合阿替利珠单抗组12例(18%)发生治疗相关严重不良事件。
- 最常见的3级或以上治疗相关不良事件为脂肪酶升高(替瑞利尤单抗联合阿替利珠单抗组6例[9%] vs 安慰剂联合阿替利珠单抗组2例[3%]);替瑞利尤单抗联合阿替利珠单抗组发生2例治疗相关死亡(发热和感染)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents, such as tiragolumab. In the CITYSCAPE trial, we aimed to assess the preliminary efficacy and safety of tiragolumab plus atezolizumab (anti-PD-L1) therapy as first-line treatment for non-small-cell lung cancer (NSCLC). METHODS: CITYSCAPE is a phase 2, randomised, double-blind, placebo-controlled trial. Patients with chemotherapy-naive, PD-L1-positive (defined as a tumour proportion score of ≥1% by 22C3 immunohistochemistry pharmDx assay; Dako, Agilent Technologies, Santa Clara, CA, USA) recurrent or metastatic NSCLC with measurable disease, Eastern Cooperative Oncology Group performance status of 0 or 1, and no EGFR or ALK alterations were enrolled from 41 clinics in Europe, Asia, and the USA. Patients were randomly assigned (1:1), via an interactive voice or web-based response system, to receive tiragolumab (600 mg) plus atezolizumab (1200 mg) or placebo plus atezolizumab intravenously once every 3 weeks. Investigators and patients were masked to treatment assignment. The co-primary endpoints were investigator-assessed objective response rate and progression-free survival as per Response Evaluation Criteria in Solid Tumors version 1.1 in the intention-to-treat population, analysed after approximately 80 progression-free survival events had been observed in the primary population. Safety was assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT03563716, and is ongoing. FINDINGS: Patients were enrolled between Aug 10, 2018, and March 20, 2019. At data cutoff for the primary analysis (June 30, 2019), 135 of 275 patients assessed for eligibility were randomly assigned to receive tiragolumab plus atezolizumab (67 [50%]) or placebo plus atezolizumab (68 [50%]). In this primary analysis, after a median follow-up of 5·9 months (4·6-7·6, in the intention-to-treat population, 21 patients (31·3% [95% CI 19·5-43·2]) in the tiragolumab plus atezolizumab group versus 11 patients (16·2% [6·7-25·7]) in the placebo plus atezolizumab group had an objective response (p=0·031). Median progression-free survival was 5·4 months (95% CI 4·2-not estimable) in the tiragolumab plus atezolizumab group versus 3·6 months (2·7-4·4) in the placebo plus atezolizumab group (stratified hazard ratio 0·57 [95% CI 0·37-0·90], p=0·015). 14 (21%) patients receiving tiragolumab plus atezolizumab and 12 (18%) patients receiving placebo plus atezolizumab had serious treatment-related adverse events. The most frequently reported grade 3 or worse treatment-related adverse event was lipase increase (in six [9%] patients in the tiragolumab plus atezolizumab group vs two [3%] in the placebo plus atezolizumab group). Two treatment-related deaths (of pyrexia and infection) occurred in the tiragolumab plus atezolizumab group. INTERPRETATION: Tiragolumab plus atezolizumab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in patients with chemotherapy-naive, PD-L1-positive, recurrent or metastatic NSCLC. Tiragolumab plus atezolizumab was well tolerated, with a safety profile generally similar to that of atezolizumab alone. These findings demonstrate that tiragolumab plus atezolizumab is a promising immunotherapy combination for the treatment of previously untreated, locally advanced unresectable or metastatic NSCLC. FUNDING: F Hoffmann-La Roche and Genentech.
引用
- Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022. PMID: 35576957. doi:10.1016/S1470-2045(22)00226-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。